113 related articles for article (PubMed ID: 12851040)
1. Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys.
Jin L; Chen IW; Chiba M; Lin JH
Xenobiotica; 2003 Jun; 33(6):643-54. PubMed ID: 12851040
[TBL] [Abstract][Full Text] [Related]
2. Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence.
Lin JH; Chiba M; Chen IW; Nishime JA; Vastag KJ
Drug Metab Dispos; 1996 Dec; 24(12):1298-306. PubMed ID: 8971134
[TBL] [Abstract][Full Text] [Related]
3. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
5. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A.
Chiba M; Hensleigh M; Lin JH
Biochem Pharmacol; 1997 Apr; 53(8):1187-95. PubMed ID: 9175724
[TBL] [Abstract][Full Text] [Related]
6. The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
Zhang F; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
Bioorg Med Chem Lett; 2003 Aug; 13(15):2573-6. PubMed ID: 12852969
[TBL] [Abstract][Full Text] [Related]
7. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Eagling VA; Wiltshire H; Whitcombe IW; Back DJ
Xenobiotica; 2002 Jan; 32(1):1-17. PubMed ID: 11824416
[TBL] [Abstract][Full Text] [Related]
8. Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: involvement of enzyme inactivation.
Lin JH; Chen IW; Chiba M; Nishime JA; Deluna FA
Drug Metab Dispos; 2000 Apr; 28(4):460-6. PubMed ID: 10725315
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
Koudriakova T; Iatsimirskaia E; Utkin I; Gangl E; Vouros P; Storozhuk E; Orza D; Marinina J; Gerber N
Drug Metab Dispos; 1998 Jun; 26(6):552-61. PubMed ID: 9616191
[TBL] [Abstract][Full Text] [Related]
10. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.
Balani SK; Woolf EJ; Hoagland VL; Sturgill MG; Deutsch PJ; Yeh KC; Lin JH
Drug Metab Dispos; 1996 Dec; 24(12):1389-94. PubMed ID: 8971147
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
12. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
Inaba T; Fischer NE; Riddick DS; Stewart DJ; Hidaka T
Toxicol Lett; 1997 Dec; 93(2-3):215-9. PubMed ID: 9486958
[TBL] [Abstract][Full Text] [Related]
13. Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
Kevin NJ; Duffy JL; Kirk BA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
Bioorg Med Chem Lett; 2003 Nov; 13(22):4027-30. PubMed ID: 14592500
[TBL] [Abstract][Full Text] [Related]
14. Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts.
Ho YF; Huang DK; Hsueh WC; Lai MY; Yu HY; Tsai TH
Life Sci; 2009 Aug; 85(7-8):296-302. PubMed ID: 19559714
[TBL] [Abstract][Full Text] [Related]
15. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.
Merry C; Barry MG; Ryan M; Tjia JF; Hennessy M; Eagling VA; Mulcahy F; Back DJ
AIDS; 1999 Oct; 13(15):F101-7. PubMed ID: 10546851
[TBL] [Abstract][Full Text] [Related]
16. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
17. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction .
Lin JH; Chiba M; Chen IW; Nishime JA; deLuna FA; Yamazaki M; Lin YJ
Drug Metab Dispos; 1999 Oct; 27(10):1187-93. PubMed ID: 10497146
[TBL] [Abstract][Full Text] [Related]
18. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
Wong SG; Fan PW; Subramanian R; Tonn GR; Henne KR; Johnson MG; Tadano Lohr M; Wong BK
Drug Metab Dispos; 2010 May; 38(5):841-50. PubMed ID: 20100816
[TBL] [Abstract][Full Text] [Related]
19. A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
Cheng Y; Rano TA; Huening TT; Zhang F; Lu Z; Schleif WA; Gabryelski L; Olsen DB; Stahlhut M; Kuo LC; Lin JH; Xu X; Jin L; Olah TV; McLoughlin DA; King RC; Chapman KT; Tata JR
Bioorg Med Chem Lett; 2002 Feb; 12(4):529-32. PubMed ID: 11844665
[TBL] [Abstract][Full Text] [Related]
20. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
Fitzsimmons ME; Collins JM
Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
